Researchers develop new generation tumor-specific pro-IL-12
Why severe depression affects women and men differently
10 January 2022‘Deltacron’ likely result of lab error: experts
10 January 2022Researchers develop new generation tumor-specific pro-IL-12
Interleukin-12 (IL-12), a potent inducer of cell-mediated immunity, can stimulate the anti-tumor effector functions of the activated T and NK cells for solid tumors rejection. However, clinical administration of IL-12 has been limited because of its short half-life, low efficacy, and dose-limiting systemic toxicity.
